Arrowhead Pharmaceuticals Reports Promising Interim Results for RNAi-Based Obesity Therapies in Phase 1/2a Trials

Reuters

Jan 06

Arrowhead Pharmaceuticals Reports Promising Interim Results for RNAi-Based Obesity Therapies in Phase 1/2a Trials

Arrowhead Pharmaceuticals Inc. has announced interim results from two Phase 1/2a clinical trials of its investigational RNA interference (RNAi) therapeutics, ARO-INHBE and ARO-ALK7, being developed as potential treatments for obesity. The preliminary data demonstrated meaningful reductions in key measures such as visceral fat, total fat, and liver fat. In obese patients with type 2 diabetes mellitus, ARO-INHBE in combination with tirzepatide showed doubled weight loss and tripled reductions in visceral, total, and liver fat compared to tirzepatide alone. The studies also reported that ARO-ALK7 was generally well tolerated as monotherapy, with no serious adverse events observed. These interim results have already been presented by the company.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arrowhead Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260106676011) on January 06, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2601892553"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2601892553\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2601892553?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-06 20:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2601892553","market":"fut","top_or_hot":-1,"title":"Arrowhead Pharmaceuticals Reports Promising Interim Results for RNAi-Based Obesity Therapies in Phase 1/2a Trials","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Arrowhead Pharmaceuticals Reports Promising Interim Results for RNAi-Based Obesity Therapies in Phase 1/2a Trials\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Arrowhead Pharmaceuticals Inc. has announced interim results from two Phase 1/2a clinical trials of its investigational RNA interference (RNAi) therapeutics, ARO-INHBE and ARO-ALK7, being developed as potential treatments for obesity. The preliminary data demonstrated meaningful reductions in key measures such as visceral fat, total fat, and liver fat. In obese patients with type 2 diabetes mellitus, ARO-INHBE in combination with tirzepatide showed doubled weight loss and tripled reductions in visceral, total, and liver fat compared to tirzepatide alone. The studies also reported that ARO-ALK7 was generally well tolerated as monotherapy, with no serious adverse events observed. These interim results have already been presented by the company.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arrowhead Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260106676011) on January 06, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Arrowhead Pharmaceuticals Reports Promising Interim Results for RNAi-Based Obesity Therapies in Phase 1/2a Trials</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nArrowhead Pharmaceuticals Reports Promising Interim Results for RNAi-Based Obesity Therapies in Phase 1/2a Trials\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-06 20:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Arrowhead Pharmaceuticals Reports Promising Interim Results for RNAi-Based Obesity Therapies in Phase 1/2a Trials\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Arrowhead Pharmaceuticals Inc. has announced interim results from two Phase 1/2a clinical trials of its investigational RNA interference (RNAi) therapeutics, ARO-INHBE and ARO-ALK7, being developed as potential treatments for obesity. The preliminary data demonstrated meaningful reductions in key measures such as visceral fat, total fat, and liver fat. In obese patients with type 2 diabetes mellitus, ARO-INHBE in combination with tirzepatide showed doubled weight loss and tripled reductions in visceral, total, and liver fat compared to tirzepatide alone. The studies also reported that ARO-ALK7 was generally well tolerated as monotherapy, with no serious adverse events observed. These interim results have already been presented by the company.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arrowhead Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260106676011) on January 06, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260106:nNDL8S5DbV:1","article_id":"2601892553","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2601892553","pubTimestamp":1767702652,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Arrowhead Pharmaceuticals Inc. has announced interim results from two Phase 1/2a clinical trials of its investigational RNA interference  therapeutics, ARO-INHBE and ARO-ALK7, being developed as potential treatments for obesity. The preliminary data demonstrated meaningful reductions in key measures such as visceral fat, total fat, and liver fat. In obese patients with type 2 diabetes mellitus, ARO-INHBE in combination with tirzepatide showed doubled weight loss and tripled reductions in visceral, total, and liver fat compared to tirzepatide alone. The studies also reported that ARO-ALK7 was generally well tolerated as monotherapy, with no serious adverse events observed. These interim results have already been presented by the company.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interp","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4588":"碎股","ARWR":"Arrowhead Research Corporation","BK4585":"ETF&股票定投概念"},"translate_title":"Arrowhead Pharmaceuticals报告了基于RNAi的肥胖疗法在1/2a期试验中有希望的中期结果","themeId":"c573bab846c0be6427fdc6152b80ce33","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ARWR":0.9},"content_text":"Arrowhead Pharmaceuticals Reports Promising Interim Results for RNAi-Based Obesity Therapies in Phase 1/2a Trials\n    \n\n        Arrowhead Pharmaceuticals Inc. has announced interim results from two Phase 1/2a clinical trials of its investigational RNA interference (RNAi) therapeutics, ARO-INHBE and ARO-ALK7, being developed as potential treatments for obesity. The preliminary data demonstrated meaningful reductions in key measures such as visceral fat, total fat, and liver fat. In obese patients with type 2 diabetes mellitus, ARO-INHBE in combination with tirzepatide showed doubled weight loss and tripled reductions in visceral, total, and liver fat compared to tirzepatide alone. The studies also reported that ARO-ALK7 was generally well tolerated as monotherapy, with no serious adverse events observed. These interim results have already been presented by the company.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arrowhead Pharmaceuticals Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260106676011) on January 06, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,express","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}